New markets for the chemicals you already make — or want to evaluate.
Better returns from products you already make. We translate your molecule into what it actually does, span the globe for every industry that needs that function, and turn the whole thing into a workflow your business runs — not a project that stops.
How PROWL works See the evidenceBusiness is about results. The goal is returns and margin.
Adjacent-market development moves both without new chemistry, a new plant or a new regulatory file — so it lands on the P&L rather than in next year's capex plan.
| Today | What moves on the P&L | |
|---|---|---|
| Adjacent selling runs as a project, then stops. | › | Adjacent selling runs as a process. |
| Molecules stay in their lane. | › | Top-line growth from products you already make. |
| Plant runs under capacity. | › | Improved ROCE from plant you already run. |
| Growth waits for capex. | › | Growth with no new capital. |
| Same markets, same buyers. | › | New customers in those markets — the ones not basic in your molecule. |
| Knowledge leaves with people. | › | Knowledge that compounds. |
Improved market success through better strategy — built with targeted artificial intelligence.
Three questions decide it: how big is the slice you'd sell into, can you charge a premium, and who do you sell through. In one engagement no source published any of them. We said so, and named them.
Building adjacent sales growth is the hard part.
Not the reading — the reading is only where it starts. Turning a molecule into revenue in an industry you have never sold to has to get past three separate walls, and only one of them is about budget.
Wall 1Finding it
The evidence is public but scattered, and most of it is hard to read on purpose: dossiers written by lawyers for regulators, patents drafted to disclose as little as the law allows, papers written for specialists in another field. The decisive line sits in a clause.
Wall 2Proving it is worth selling
That needs someone who reads a patent and knows what the molecule really does, and knows which application is worth a call, and can build the case management will back. Most companies have one or two such people. They are already committed.
Wall 3Doing it again next quarter
Done properly the work is a team assembled across functions and held together for months. That is affordable once. So adjacent growth gets done properly once — and then not again.
And no, search does not solve it.
Why not a search engineIt ranks popularity, not evidence
Search returns what is linked to, not what is load-bearing. The document that decides whether your molecule can serve an application is often cited by nobody, written for a different discipline, and sitting on page nine.
Why not a general AIIt answers from memory, not from the record
A general-purpose model answers from what it absorbed in training — a summary of the internet at some past date, not a reading of the primary record. It will give you a fluent answer with no source you can check, and it cannot tell you what it failed to find.
Why not your own filesThe inside view is stale, and already explored
The material inside the company is dated, and the same ground has been walked repeatedly. The places that are genuinely new are, by definition, the ones nobody in the building has looked at.
It is a new workflow, not a search.
A search answers a question once and leaves the business unchanged. A workflow runs on a cadence and is fitted to your company — your vocabulary, what you already sell, your own systems wired in alongside the public record. That is what decides whether the returns are a one-off.
Tailored AI is what makes it possible. A workflow like this was never really an option before, because the reading alone consumed the budget — so the work could only be afforded once. An engine fitted to your vocabulary and your evidence does that reading at a cost that makes repeating it sensible, and it remembers why every judgement was made, which is what lets a cadence run at all. It decides nothing. A person still signs.
Chemistry into performance, into markets
Translating what your molecule does, spanning every industry that needs it, and testing each candidate for real, worth it, winnable.
Embedding itA cadence, not a project
What it does to the P&L when it runs continuously — and why it normally doesn't.
What you keepYour vocabulary, your evidence
A sourced library in your own words, fitted to your business. You own it, and it does not depreciate.
Two engagements, and the new market applications they found.
candidate markets found for one established chemical — 39 already served, and subtracted before ranking
candidate markets for a fermentation-derived biosurfactant, and three questions no source publishes at all
from starting to a sourced go-to-market foundation on that first engagement, with the gaps named
Start with one chemistry. Let the result decide the rest.
A low-cost test on one product, worked end to end and judged on what comes back. You will know within minutes whether the leads are credible — you know your own markets. A cheap “nothing here” is a legitimate answer.
571-276-9104 · Okatie, South Carolina
LinkedIn: jimpuckace